# Walking Fish Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/walking-fish-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.walkingfishtx.com
- Total disclosed funding: $41M
- Latest round: Series A (Feb 16, 2022)
- Investors on record: 6

## About

Walking Fish Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative B cell therapeutics for oncology, rare diseases, and autoimmune disorders.Founded in 2019 and headquartered in South San Francisco, US, Walking Fish Therapeutics, Inc. specializes in B cell therapeutics. The company raised USD 12.7 mn in Series A funding in February 2022, co-led by First Spark Ventures and Northpond Ventures, to advance its therapeutic pipeline. Founder Thomas Brennan has a history of entrepreneurship in the biotechnology sector, contributing to the company’s strategic direction. The company has engaged in 2 investment deals to date, with a current valuation of USD 90.641 mn.Walking Fish Therapeutics develops a range of B cell therapeutics, specifically targeting oncology, rare diseases, regenerative medicine, and autoimmune conditions. Their pipeline includes innovative treatments utilizing recombinant antibody production, aimed at addressing unmet medical needs in various therapeutic areas.The company’s revenue model is primarily based on funding for its research and development efforts, with recent funding rounds contributing to their ongoing projects and therapeutic advances. The flagship therapeutic programs are expected to drive future revenues as they progress through clinical development.In February 2022, Walking Fish Therapeutics secured USD 12.7 mn in Series A funding to enhance its pipeline of B cell therapeutics aimed at oncology, rare diseases, regenerative medicine, and autoimmune conditions. The company plans to leverage this funding to support the development of new therapeutics and may explore expansion into additional global markets as their products advance.

## Funding rounds

- Series A, Feb 16, 2022, $13M — Terra Magnum Capital Partners, Northpond Ventures, First Spark Ventures
- Series A, Aug 27, 2021, $29M — Illumina Ventures, Emerson Collective, Quan Capital

## Investors

- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series A
- Emerson Collective — Series A
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series A
- Terra Magnum Capital Partners (https://capitalatlas.ai/funds/terra-magnum-capital-partners) — Series A
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A
- First Spark Ventures (https://capitalatlas.ai/funds/first-spark-ventures) — Series A